Default Category
-
Kidder, Peabody & Co.: creando beneficios etéreos
Simons, Robert L.; Davila, AntonioCase HBS-102S16Accounting and ControlEl 17 de abril de 1994, Kidder, Peabody & Co. anunció un cargo de $ 350 millones de dólares contra las ganancias resultantes del descubrimiento de los beneficios de explotación falsas. Ese mismo día, la terminación del empleo de Joseph Jett con la compañía se hizo pública. Al ilustrar la mecánica de la contabilidad de bonos, este caso se describe la estrategia de negociación que condujo a la creación de falsos beneficios. También se discuten los ...Starting at €8.20
-
Dissension in the Ranks? (A) (Spanish version)
Simons, Robert L.; Weston, Hilary A.Case HBS-102S40Leadership and People Managementhbsp.harvard.edu/jdotStarting at €8.20
-
Dissension in the Ranks? (B) (Spanish version)
Simons, Robert L.Case HBS-109S07Leadership and People Managementhbsp.harvard.edu/jdotStarting at €5.74
-
Merck: La administración de Vioxx (D)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S05Knowledge and CommunicationStarting at €5.74
-
Merck: La administración de Vioxx (G)
Simons, Robert L.; Kindred, NatalieCase HBS-111S08Knowledge and CommunicationStarting at €8.20
-
General Electric's Revolutionary (Spanish version)
Bower, Joseph L.; Dial, JayCase HBS-308S36StrategyDescribes the work of Jack Welch as CEO of General Electric from 1981 to 1992, focusing particularly on his transformation of the company's portfolio through extensive dispositions and acquisitions and the company's culture through a mandated process called "work out." To a considerable extent, the case tells the story in Welch's own words drawing on earlier cases on Welch prepared by Richard Hammermesh and Frank Aguilar, as well as a 1991 interv...Starting at €8.20
-
-
Merck: Managing Vioxx (A)-(G), Teaching Note
Kindred, Natalie; Simons, Robert L.Teaching Note HBS-109087-ETeaching Note for [109080], [109081], [109082], [109083], [109084], [109085], and [109086].Starting at €0.00
-
Pfizer: Letter from the Chairman (B)
Simons, Robert L.; Rosenberg, KathrynCase HBS-110004-EAccounting and ControlThis case continues the story begun in "Pfizer: A Letter From The Chairman" (HBS No. 9-110-003), revealing the letter Chairman and CEO Jeff Kindler wrote for the 2008 Annual Report.Starting at €5.74
-
Pfizer: Letter from the Chairman (A) and (B), Teaching Note
Simons, Robert L.; Rosenberg, KathrynTeaching Note HBS-110067-EAccounting and ControlTeaching Note for 110003 and 110004.Starting at €0.00